lamivudine 150 MG zidovudine 300 MG Oral Tablet

1 INDICATIONS AND USAGE Lamivudine and Zidovudine tablets, a combination of 2 nucleoside analogues, are indicated in combination with other antiretrovirals for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. Lamivudine and Zidovudine tablets, a combination of 2 nucleoside analogue reverse transcriptase inhibitors, are indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. (1)

American Health Packaging

FDA Reported Adverse Reactions
`[1] drug ineffective` `[2] nausea` `[3] fatigue` `[4] pain` `[5] diarrhoea` `[6] off label use` `[7] headache` `[8] vomiting` `[9] arthralgia` `[10] dyspnoea`

3 years ago

OVAL WHITE J 58

16 HOW SUPPLIED/STORAGE AND HANDLING Lamivudine and Zidovudine Tablets USP, containing 150 mg lamivudine and 300 mg zidovudine, are white to off-white, modified capsule shaped, biconvex, film-coated tablets with deep breakline in between ‘J’ and ‘58’ on one side and deep breakline on the other side. They are available as follows: Unit dose packages of 30 (5 x 6) NDC 68084-416-25 Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] FOR YOUR PROTECTION: Do not use if blister is torn or broken.

More pills like OVAL J 58

DISCLAIMER:

"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."

"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."

"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."

PillSync may earn a commission via links on our site

lamivudine 150 MG zidovudine 300 MG Oral Tablet

FDA Reported Adverse Reactions [1] drug ineffective [2] nausea [3] fatigue [4] pain [5] diarrhoea [6] off label use [7] headache [8] vomiting [9] arthralgia [10] dyspnoea

OVAL WHITE J 58

More pills like OVAL J 58

FDA Reported Adverse Reactions
`[1] drug ineffective` `[2] nausea` `[3] fatigue` `[4] pain` `[5] diarrhoea` `[6] off label use` `[7] headache` `[8] vomiting` `[9] arthralgia` `[10] dyspnoea`